Delaware
|
001-33380
|
87-0792558
|
||
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
1901 Campus Place
Louisville, Kentucky
|
40299
|
|
(Address of principal executive offices)
|
(Zip Code)
|
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 | Results of Operations and Financial Condition. |
Item 9.01 | Financial Statements and Exhibits. |
(d) | Exhibits |
99.1 | Press Release of PharMerica Corporation dated February 26, 2016. |
PHARMERICA CORPORATION
|
|||
Date: February 26, 2016
|
By:
|
/s/ David W. Froesel, Jr.
|
|
David W. Froesel, Jr.
|
|||
Executive Vice President, Chief Financial Officer and Treasurer
|
Exhibit No.
|
Description
|
Press Release of PharMerica Corporation dated February 26, 2016.
|
Contact:
|
David W. Froesel, Jr.
|
Executive Vice President,
|
Chief Financial Officer and Treasurer
|
(502) 627-7950
|
4Q’15 Results
|
Comparison to
4Q’14
|
Comparison to
3Q’15
|
|
Revenue
|
$520.6 million
|
Decrease of 0.6%
|
Increase of 4.4%
|
Adjusted EBITDA
|
$37.1 million
|
Decrease of 0.5%
|
Increase of 11.4%
|
Adjusted diluted earnings per share
|
$0.45
|
Decrease of 2.2%
|
Increase of 18.4%
|
Gross profit
|
$86.7 million
|
Decrease of 8.2%
|
Increase of 10.3%
|
Selling, general and administrative
|
$55.4 million
|
Improvement of 15.0%
|
Increase of 5.1%
|
Generic drug dispensing rate
|
86.3%
|
Increase of 140 basis points
|
Decrease of 20 basis points
|
· | Revenue in the range of $2.125 billion to $2.150 billion; |
· | Adjusted diluted earnings per share in the range of $1.95 to $2.05; and |
· | Adjusted EBITDA in the range of $130.3 million to $135.3 million. |
Ø | Key Comparisons of Fourth Quarters Ended December 31, 2015 and 2014: |
· | Revenues for the fourth quarter of 2015 were $520.6 million compared with $523.5 million for the fourth quarter of 2014. The decrease in revenues was driven by a decline of 1.1 million in prescriptions dispensed offset by significant growth in the Company’s specialty pharmacy businesses. |
· | Gross profit for the fourth quarter of 2015 was $86.7 million compared with $94.4 million in the fourth quarter of 2014. The decrease in gross profit was driven by the decrease in prescriptions dispensed mentioned above partially offset by an increase in gross profit from the Company’s specialty pharmacy businesses. |
· | Selling, general and administrative expenses were $55.4 million, or 10.6% of revenues, for the three months ended December 31, 2015, compared to $65.2 million, or 12.5% of revenues, for the three months ended December 31, 2014. The decrease of $9.8 million was due to cost improvements and a reduction in bad debt expense as the Company improved its client mix. |
· | Adjusted EBITDA for the fourth quarter of 2015 was $37.1 million compared with $37.3 million in the fourth quarter of 2014, a decrease of 0.5%. |
· | Net income for the fourth quarter of 2015 was $20.2 million, or $0.66 diluted earnings per share, compared to net income of $3.2 million, or $0.10 diluted earnings per share, for the same period in 2014. Adjusted diluted earnings per share was $0.45 in the fourth quarter of 2015 compared to $0.46 in the fourth quarter of 2014. |
· | Cash flows used in operating activities for the fourth quarter of 2015 were $41.1 million compared with cash flows provided by operating activities for the fourth quarter of 2014 of $50.8 million. |
Ø | Key Comparisons of the Years Ended December 31, 2015 and 2014: |
2015 Results
|
Comparison to 2014
|
|
Revenue
|
$2,028.5 million
|
Increase of 7.1%
|
Adjusted EBITDA
|
$141.0 million
|
Increase of 8.0%
|
Adjusted diluted earnings per share
|
$1.69
|
Even
|
Gross profit
|
$335.1 million
|
Decrease of 1.2%
|
Selling, general and administrative
|
$222.5 million
|
Improvement of 5.8%
|
Generic drug dispensing rate
|
86.0%
|
Increase of 110 basis points
|
· | Revenues for the year ended December 31, 2015, were $2,028.5 million compared with $1,894.5 million for the year ended December 31, 2014. The increase was driven by recent acquisitions, growth in the Company’s specialty pharmacy businesses and branded drug inflation. |
· | Gross profit for the year ended December 31, 2015, was $335.1 million compared with $339.3 million for the year ended December 31, 2014. The decrease in gross profit was driven by higher drug costs under the Company’s prime vendor agreement with Cardinal Health and volume decreases in the long-term care pharmacy business. |
· | Selling, general and administrative expenses were $222.5 million, or 11.0% of revenues, for the year ended December 31, 2015, compared to $236.3 million, or 12.5% of revenues, for the year ended December 31, 2014. The decrease of $13.8 million is due to cost improvements and a reduction in bad debt expense as the Company improved its client mix. |
· | Adjusted EBITDA for the year ended December 31, 2015, was $141.0 million compared with $130.6 million for the year ended December 31, 2014, an increase of 8.0%. |
· | Net income for the year ended December 31, 2015, was $35.1 million, or $1.14 diluted earnings per share, compared to net income of $6.8 million, or $0.22 diluted earnings per share, for the same period in 2014. Net income for the years ended December 31, 2015 and 2014 was adversely impacted by $13.3 million and $37.3 million of pre-tax charges for settlement and litigation matters, respectively. Adjusted diluted earnings per share was $1.69 for both years ended December 31, 2015 and 2014. |
· | Cash provided by operating activities aggregated $18.5 million for the year ended December 31, 2015 compared to $48.4 million for the year ended December 31, 2014. The $29.9 million decrease in cash provided by operating activities is due to legal settlement payments of $23.4 million that were made in 2015, a slight increase in trade accounts receivable and an increase in income tax receivables. Additionally, the prime vendor payment to Cardinal Health is payable every Friday. The payment due on New Year’s Day, Friday, January 1, 2016, of $21.0 million was accelerated to Thursday, December 31, 2015, in accordance with the terms of the contract. These decreases were partially offset by $48.8 million in AmerisourceBergen drug purchase payments withheld in the first quarter of 2015 and an increase in net income for the year ended December 31, 2015. |
Three Months Ended December 31,
|
Year Ended
|
|||||||||||||||||||||||||||||||
2014
|
2015
|
2014
|
2015
|
|||||||||||||||||||||||||||||
Amount
|
% of
Revenues
|
Amount
|
% of
Revenues
|
Amount
|
% of
Revenues
|
Amount
|
% of
Revenues
|
|||||||||||||||||||||||||
Revenues
|
$
|
523.5
|
100.0
|
%
|
$
|
520.6
|
100.0
|
%
|
$
|
1,894.5
|
100.0
|
%
|
$
|
2,028.5
|
100.0
|
%
|
||||||||||||||||
Cost of goods sold
|
429.1
|
82.0
|
433.9
|
83.3
|
1,555.2
|
82.1
|
1,693.4
|
83.5
|
||||||||||||||||||||||||
Gross profit
|
94.4
|
18.0
|
86.7
|
16.7
|
339.3
|
17.9
|
335.1
|
16.5
|
||||||||||||||||||||||||
Selling, general and administrative expenses
|
65.2
|
12.5
|
55.4
|
10.6
|
236.3
|
12.5
|
222.5
|
11.0
|
||||||||||||||||||||||||
Amortization expense
|
6.5
|
1.2
|
8.0
|
1.5
|
20.1
|
1.0
|
28.6
|
1.4
|
||||||||||||||||||||||||
Merger, acquisition, integration costs and other charges
|
3.3
|
0.6
|
6.1
|
1.2
|
13.6
|
0.7
|
21.3
|
1.0
|
||||||||||||||||||||||||
Settlement, litigation and other related charges
|
8.4
|
1.6
|
2.0
|
0.4
|
37.3
|
2.0
|
13.3
|
0.7
|
||||||||||||||||||||||||
Restructuring and impairment charges
|
0.1
|
-
|
0.2
|
-
|
3.3
|
0.2
|
0.5
|
-
|
||||||||||||||||||||||||
Hurricane Sandy disaster recoveries
|
(1.8
|
)
|
(0.3
|
)
|
(5.0
|
)
|
(1.0
|
)
|
(1.7
|
)
|
(0.1
|
)
|
(4.9
|
)
|
(0.2
|
)
|
||||||||||||||||
Operating income
|
12.7
|
2.4
|
20.0
|
3.9
|
30.4
|
1.6
|
53.8
|
2.6
|
||||||||||||||||||||||||
Interest expense, net
|
3.0
|
0.6
|
1.2
|
0.3
|
9.9
|
0.5
|
6.6
|
0.3
|
||||||||||||||||||||||||
Loss on extinguishment of debt
|
-
|
-
|
-
|
-
|
4.3
|
0.2
|
-
|
-
|
||||||||||||||||||||||||
Income before income taxes
|
9.7
|
1.8
|
18.8
|
3.6
|
16.2
|
0.9
|
47.2
|
2.3
|
||||||||||||||||||||||||
Provision (benefit) for income taxes
|
6.5
|
1.2
|
(1.4
|
)
|
(0.3
|
)
|
9.4
|
0.5
|
12.1
|
0.6
|
||||||||||||||||||||||
Net income
|
$
|
3.2
|
0.6
|
%
|
$
|
20.2
|
3.9
|
%
|
$
|
6.8
|
0.4
|
%
|
$
|
35.1
|
1.7
|
%
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
|||||||||||||||
2014
|
2015
|
2014
|
2015
|
|||||||||||||
Earnings per common share:
|
||||||||||||||||
Basic
|
$
|
0.11
|
$
|
0.66
|
$
|
0.23
|
$
|
1.16
|
||||||||
Diluted
|
$
|
0.10
|
$
|
0.66
|
$
|
0.22
|
$
|
1.14
|
||||||||
Shares used in computing earnings per common share:
|
||||||||||||||||
Basic
|
30,097,829
|
30,447,228
|
29,983,428
|
30,363,588
|
||||||||||||
Diluted
|
30,721,947
|
31,009,368
|
30,649,131
|
30,767,366
|
(As Adjusted)
Dec. 31,
2014
|
Dec. 31,
2015
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
33.3
|
$
|
23.1
|
||||
Accounts receivable, net
|
195.4
|
200.5
|
||||||
Inventory
|
135.5
|
155.2
|
||||||
Deferred tax assets, net
|
42.8
|
41.8
|
||||||
Income taxes receivable
|
-
|
10.5
|
||||||
Prepaids and other assets
|
90.3
|
52.4
|
||||||
497.3
|
483.5
|
|||||||
Equipment and leasehold improvements
|
196.4
|
218.5
|
||||||
Accumulated depreciation
|
(125.0
|
)
|
(144.0
|
)
|
||||
71.4
|
74.5
|
|||||||
Goodwill
|
323.6
|
371.0
|
||||||
Intangible assets, net
|
177.6
|
190.2
|
||||||
Other
|
4.1
|
34.5
|
||||||
$
|
1,074.0
|
$
|
1,153.7
|
|||||
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
96.0
|
$
|
71.7
|
||||
Salaries, wages and other compensation
|
35.1
|
30.6
|
||||||
Current portion of long-term debt
|
6.3
|
11.6
|
||||||
Income taxes payable
|
2.3
|
-
|
||||||
Other accrued liabilities
|
38.5
|
27.5
|
||||||
178.2
|
141.4
|
|||||||
Long-term debt
|
344.4
|
415.7
|
||||||
Other long-term liabilities
|
57.6
|
56.5
|
||||||
Deferred tax liabilities
|
15.7
|
20.7
|
||||||
Commitments and contingencies
|
||||||||
Stockholders' equity:
|
||||||||
Preferred stock, $0.01 par value per share; 1,000,000 shares authorized and no shares issued, December 31, 2014 and 2015
|
-
|
-
|
||||||
Common stock, $0.01 par value per share; 175,000,000 shares authorized; 32,725,786 and 33,237,732 shares issued as of December 31, 2014 and 2015, respectively
|
0.3
|
0.3
|
||||||
Capital in excess of par value
|
394.1
|
404.6
|
||||||
Retained earnings
|
117.0
|
152.1
|
||||||
Treasury stock at cost, 2,617,305 and 2,776,875 shares at December 31, 2014 and 2015, respectively
|
(33.3
|
)
|
(37.6
|
)
|
||||
478.1
|
519.4
|
|||||||
$
|
1,074.0
|
$
|
1,153.7
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
|||||||||||||||
2014
|
2015
|
2014
|
2015
|
|||||||||||||
Cash flows provided by (used in) operating activities:
|
||||||||||||||||
Net income
|
$
|
3.2
|
$
|
20.2
|
$
|
6.8
|
$
|
35.1
|
||||||||
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
|
||||||||||||||||
Depreciation
|
5.8
|
5.9
|
20.3
|
23.1
|
||||||||||||
Amortization
|
6.5
|
8.0
|
20.1
|
28.6
|
||||||||||||
Merger, acquisition, integration costs and other charges
|
-
|
-
|
2.5
|
-
|
||||||||||||
Hurricane Sandy disaster costs (recoveries)
|
(1.8
|
)
|
-
|
(1.8
|
)
|
-
|
||||||||||
Stock-based compensation and deferred compensation
|
2.3
|
2.4
|
8.0
|
7.8
|
||||||||||||
Amortization of deferred financing fees
|
0.1
|
0.2
|
1.9
|
0.6
|
||||||||||||
Deferred income taxes
|
1.0
|
(0.6
|
)
|
(2.3
|
)
|
4.0
|
||||||||||
Gain (loss) on disposition of equipment
|
0.1
|
(0.1
|
)
|
-
|
-
|
|||||||||||
Gain on acquisition/disposition
|
-
|
(0.4
|
)
|
(0.2
|
)
|
(0.4
|
)
|
|||||||||
Loss on extinguishment of debt
|
-
|
-
|
4.3
|
-
|
||||||||||||
Other
|
0.3
|
(0.1
|
)
|
0.4
|
-
|
|||||||||||
Change in operating assets and liabilities:
|
||||||||||||||||
Accounts receivable, net
|
18.7
|
(3.6
|
)
|
29.1
|
(2.4
|
)
|
||||||||||
Inventory
|
(2.5
|
)
|
(34.0
|
)
|
(18.8
|
)
|
(15.9
|
)
|
||||||||
Prepaids and other assets
|
(23.0
|
)
|
(8.1
|
)
|
(49.2
|
)
|
4.2
|
|||||||||
Accounts payable
|
20.0
|
(12.1
|
)
|
(2.9
|
)
|
(24.0
|
)
|
|||||||||
Salaries, wages and other compensation
|
(2.2
|
)
|
(3.8
|
)
|
(4.9
|
)
|
(4.7
|
)
|
||||||||
Other accrued and long-term liabilities
|
14.7
|
(14.2
|
)
|
31.3
|
(24.4
|
)
|
||||||||||
Change in income taxes payable (receivable)
|
7.6
|
(0.7
|
)
|
7.2
|
(10.7
|
)
|
||||||||||
Excess tax benefit from stock-based compensation
|
-
|
(0.1
|
)
|
(3.4
|
)
|
(2.4
|
)
|
|||||||||
Net cash provided by (used in) operating activities
|
50.8
|
(41.1
|
)
|
48.4
|
18.5
|
|||||||||||
Cash flows provided by (used in) investing activities:
|
||||||||||||||||
Purchase of equipment and leasehold improvements
|
(6.6
|
)
|
(6.3
|
)
|
(25.6
|
)
|
(23.9
|
)
|
||||||||
Hurricane Sandy insurance recovery
|
-
|
3.3
|
-
|
3.3
|
||||||||||||
Acquisitions, net of cash acquired
|
(8.9
|
)
|
(62.7
|
)
|
(133.7
|
)
|
(83.6
|
)
|
||||||||
Cash proceeds from sale of assets
|
-
|
(0.1
|
)
|
0.1
|
0.1
|
|||||||||||
Cash proceeds from dispositions
|
1.8
|
-
|
2.2
|
-
|
||||||||||||
Net cash used in investing activities
|
(13.7
|
)
|
(65.8
|
)
|
(157.0
|
)
|
(104.1
|
)
|
||||||||
Cash flows provided by (used in) financing activities:
|
||||||||||||||||
Repayments of long-term debt
|
-
|
(2.8
|
)
|
(231.3
|
)
|
(5.6
|
)
|
|||||||||
Proceeds from long-term debt
|
-
|
-
|
225.0
|
-
|
||||||||||||
Net activity of long-term revolving credit facility
|
(10.9
|
)
|
92.0
|
125.0
|
82.0
|
|||||||||||
Payment of debt issuance costs
|
-
|
-
|
(2.7
|
)
|
-
|
|||||||||||
Net activity of capital lease obligations
|
-
|
0.6
|
-
|
0.1
|
||||||||||||
Issuance of common stock
|
-
|
0.1
|
3.4
|
0.8
|
||||||||||||
Treasury stock at cost
|
-
|
-
|
(5.1
|
)
|
(4.3
|
)
|
||||||||||
Excess tax benefit from stock-based compensation
|
-
|
0.1
|
3.4
|
2.4
|
||||||||||||
Net cash (used in) provided by financing activities
|
(10.9
|
)
|
90.0
|
117.7
|
75.4
|
|||||||||||
Change in cash and cash equivalents
|
26.2
|
(16.9
|
)
|
9.1
|
(10.2
|
)
|
||||||||||
Cash and cash equivalents at beginning of period
|
7.1
|
40.0
|
24.2
|
33.3
|
||||||||||||
Cash and cash equivalents at end of period
|
$
|
33.3
|
$
|
23.1
|
$
|
33.3
|
$
|
23.1
|
||||||||
Supplemental information:
|
||||||||||||||||
Cash paid for interest
|
$
|
2.2
|
$
|
2.3
|
$
|
7.8
|
$
|
8.5
|
||||||||
Cash paid for taxes
|
$
|
(0.4
|
)
|
$
|
-
|
$
|
5.3
|
$
|
19.4
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
|||||||||||||||
2014
|
2015
|
2014
|
2015
|
|||||||||||||
Pharmacy data:
|
||||||||||||||||
Prescriptions dispensed (in thousands)
|
9,491
|
8,411
|
35,003
|
34,124
|
||||||||||||
Revenue per prescription dispensed
|
$
|
55.16
|
$
|
61.60
|
$
|
54.12
|
$
|
59.37
|
||||||||
Gross profit per prescription dispensed
|
$
|
9.95
|
$
|
10.01
|
$
|
9.69
|
$
|
9.75
|
(In millions)
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
||||||||||||||
2014
|
2015
|
2014
|
2015
|
|||||||||||||
Net income
|
$
|
3.2
|
$
|
20.2
|
$
|
6.8
|
$
|
35.1
|
||||||||
Add:
|
||||||||||||||||
Interest expense, net
|
3.0
|
1.2
|
9.9
|
6.6
|
||||||||||||
Merger, acquisition, integration costs and other charges
|
3.3
|
6.1
|
12.9
|
21.3
|
||||||||||||
Settlement, litigation and other related charges
|
8.4
|
2.0
|
37.3
|
13.3
|
||||||||||||
California Medicaid recoupment (reversal)
|
-
|
(2.5
|
)
|
-
|
(2.5
|
)
|
||||||||||
Restructuring and impairment charges
|
0.1
|
0.2
|
3.3
|
0.5
|
||||||||||||
Loss on extinguishment of debt
|
-
|
-
|
4.3
|
-
|
||||||||||||
Hurricane Sandy disaster recoveries
|
(1.8
|
)
|
(5.0
|
)
|
(1.7
|
)
|
(4.9
|
)
|
||||||||
Stock-based compensation and deferred compensation
|
2.3
|
2.4
|
8.0
|
7.8
|
||||||||||||
Provision for income taxes
|
6.5
|
(1.4
|
)
|
9.4
|
12.1
|
|||||||||||
Depreciation and amortization expense
|
12.3
|
13.9
|
40.4
|
51.7
|
||||||||||||
Adjusted EBITDA
|
$
|
37.3
|
$
|
37.1
|
$
|
130.6
|
$
|
141.0
|
||||||||
Adjusted EBITDA margin
|
7.1
|
%
|
7.1
|
%
|
6.9
|
%
|
7.0
|
%
|
(In whole numbers)
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
||||||||||||||
2014
|
2015
|
2014
|
2015
|
|||||||||||||
Diluted earnings per share
|
$
|
0.10
|
$
|
0.66
|
$
|
0.22
|
$
|
1.14
|
||||||||
Add:
|
||||||||||||||||
Diluted earnings per share impact of:
|
||||||||||||||||
Merger, acquisition, integration costs and other charges
|
0.08
|
0.11
|
0.27
|
0.43
|
||||||||||||
Settlement, litigation and other related charges
|
0.11
|
0.05
|
0.77
|
0.27
|
||||||||||||
California Medicaid recoupment (reversal)
|
-
|
(0.05
|
)
|
-
|
(0.05
|
)
|
||||||||||
Loss on extinguishment of debt
|
-
|
-
|
0.09
|
-
|
||||||||||||
Restructuring and impairment charges
|
-
|
-
|
0.07
|
0.01
|
||||||||||||
Hurricane Sandy disaster recoveries
|
(0.04
|
)
|
(0.10
|
)
|
(0.04
|
)
|
(0.10
|
)
|
||||||||
Stock-based compensation and deferred compensation
|
0.05
|
0.04
|
0.17
|
0.16
|
||||||||||||
Impact of discrete items and non-recurring charges on tax provision
|
0.16
|
(0.26
|
)
|
0.14
|
(0.17
|
)
|
||||||||||
Adjusted diluted earnings per share
|
$
|
0.46
|
$
|
0.45
|
$
|
1.69
|
$
|
1.69
|
(In millions)
|
Three Months Ended
December 31,
|
Year Ended
December 31,
|
||||||||||||||
2014
|
2015
|
2014
|
2015
|
|||||||||||||
Adjusted EBITDA
|
$
|
37.3
|
$
|
37.1
|
$
|
130.6
|
$
|
141.0
|
||||||||
Interest expense, net
|
(3.0
|
)
|
(1.2
|
)
|
(9.9
|
)
|
(6.6
|
)
|
||||||||
Merger, acquisition, integration costs and other charges
|
(11.8
|
)
|
(0.8
|
)
|
(52.8
|
)
|
(27.7
|
)
|
||||||||
Provision for bad debt
|
6.6
|
(1.6
|
)
|
23.2
|
7.9
|
|||||||||||
Amortization of deferred financing fees
|
0.1
|
0.2
|
1.9
|
0.6
|
||||||||||||
Loss (gain) on disposition of equipment
|
-
|
(0.1
|
)
|
-
|
-
|
|||||||||||
Gain on acquisition
|
-
|
(0.4
|
)
|
(0.2
|
)
|
(0.4
|
)
|
|||||||||
Provision for income taxes
|
(6.5
|
)
|
1.4
|
(9.4
|
)
|
(12.1
|
)
|
|||||||||
Deferred income taxes
|
1.0
|
(0.6
|
)
|
(2.3
|
)
|
4.0
|
||||||||||
Changes in federal and state income tax payable
|
7.6
|
(0.7
|
)
|
7.2
|
(10.7
|
)
|
||||||||||
Excess tax benefit from stock-based compensation
|
-
|
(0.1
|
)
|
(3.4
|
)
|
(2.4
|
)
|
|||||||||
Changes in assets and liabilities
|
19.1
|
(74.2
|
)
|
(36.9
|
)
|
(75.1
|
)
|
|||||||||
Other
|
0.4
|
(0.1
|
)
|
0.4
|
-
|
|||||||||||
Net cash flows provided by (used in) operating activities
|
$
|
50.8
|
$
|
(41.1
|
)
|
$
|
48.4
|
$
|
18.5
|